Correction

Efficacy and Safety of Baricitinib in Japanese Patients with Active Rheumatoid Arthritis Receiving Background Methotrexate Therapy: A 12-week, Double-blind, Randomized Placebo-controlled Study

Tanaka Y, Emoto K, Cai Z, Aoki T, Schlichting D, Rooney T, et al. Efficacy and safety of baricitinib in Japanese patients with active rheumatoid arthritis receiving background methotrexate therapy: a 12-week, double-blind, randomized placebo-controlled study. *J Rheumatol* 2016;43:504-11. In the Materials and Methods section, fifth paragraph, this sentence should read as follows:

A minimal clinically important difference (MCID) in HAQ-DI was defined as a change from baseline of ≤ -0.22 . [Not ≥ -0.22 .]

We regret the error.

doi:10.3899/jrheum.150613.C1